基于间充质干细胞治疗心肌梗死的临床前研究进展  

Progress of Preclinical Research on the Treatment of Myocardial Infarction based on Mesenchymal Stem Cells

作　　者：徐新茹 孙浩丹 王海萍[1] XU Xinru;SUN Haodan;WANG Haiping(Hebei North University,Zhangjiakou 075000,China)

机构地区：[1]河北北方学院,张家口075000

出　　处：《中国细胞生物学学报》2025年第4期959-967,共9页Chinese Journal of Cell Biology

基　　金：河北省自然科学基金(批准号:C2019405091);河北省高等学校科学技术研究项目(批准号:ZD2019066)资助的课题。

摘　　要：心肌梗死(myocardial infarction, MI)指由于冠状动脉粥样硬化斑块急性破裂或侵蚀,诱使血小板激活,引起心肌供氧与需氧失衡,继发冠状动脉血栓性阻塞,导致心肌损伤、坏死等。目前,临床常用治疗MI的手段已显著降低了患者死亡率,但并发症和最佳血运重建策略尚未明确确定。当前,诸多临床前和临床研究已证实间充质干细胞(mesenchymal stem cells, MSCs)治疗MI的优势。然而,干细胞植入受损心肌的应用仍然面临诸多限制。所以迫切需要一些手段与干细胞协同作用。该文系统综述了间充质干细胞的治疗潜力、改善策略及其目前在临床应用中的研究进展。MI(myocardial infarction)refers to the acute rupture or erosion of atherosclerotic plaques in the coronary arteries,which activates platelets and leads to an imbalance between myocardial oxygen supply and demand.This subsequently results in thrombotic occlusion of the coronary arteries,causing myocardial injury and necrosis.Currently,the clinical treatment methods commonly used for MI have significantly reduced the mortality rate of patients.However,the complications and the optimal revascularization strategy have not yet been clearly defined.At present,a large number of preclinical and clinical studies have confirmed the advantages of MSCs(mes-enchymal stem cells)in the treatment of MI.However,the application of stem cell implantation into damaged myo-cardium still faces numerous limitations.Therefore,there is an urgent need for some means to act synergistically with stem cells.This article systematically reviews the therapeutic potential of mesenchymal stem cells,improve-ment strategies,and the current research progress of their clinical applications.

关 键 词：间充质干细胞 心肌梗死 干细胞移植 临床研究 

分 类 号：R54[医药卫生—心血管疾病]